SEC Form 10-K filed by MAIA Biotechnology Inc.
$MAIA
Biotechnology: Pharmaceutical Preparations
Health Care
Unavailable
Unavailable
Save time and jump to the most important pieces.
Poster highlights potential predictive biomarker for therapeutic response in advanced non-small cell lung cancer (NSCLC) MAIA Biotechnology, Inc., (NYSE:MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced that an abstract detailing a potential predictive biomarker for THIO treatment was selected for poster presentation at the European Lung Cancer Congress 2025 (ELCC 2025) taking place, March 26-29, in Paris, France. ELCC is a program of the European Society for Medical Oncology (ESMO). "We are proud to join ELCC 2025, a premier conference focused directly on the science of thoracic oncology," said V
Acclaimed academic researcher has led 40+ multicenter phase 2 and phase 3 clinical studies MAIA Biotechnology, Inc., (NYSE:MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced the appointment of Professor Saadettin Kilickap, M.D. to its Scientific Advisory Board (SAB). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240321173734/en/Professor Saadettin Kilickap, M.D., Scientific Advisor to MAIA Biotechnology (Photo: Business Wire) Dr. Kilickap is a professor at the Istinye University Faculty of Medicine, Department of Medical Oncology, Liv Hos
New Scientific Advisory Board member played instrumental role in FDA approval and commercialization of multiple blockbuster products CHICAGO, IL, Feb. 27, 2024 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc., (NYSE:MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced the appointment of immuno-oncology leader Remus Vezan, M.D., Ph.D., to its Scientific Advisory Board (SAB). With over 20 years of academic and biopharmaceutical industry experience, Dr. Vezan is a highly regarded leader in drug development of novel therapeutic modalities, including cell and gene therapies, and played a pivotal role in the devel
Lead compound THIO (ateganosine) is the only clinical-stage telomere-targeting anticancer agent throughout the field of cancer discovery Potential FDA filings in 2026 for accelerated approval from THIO-101 and early full approval from THIO-104 Full Shareholder Letter available in Investors section of MAIA's corporate website MAIA Biotechnology, Inc., (NYSE:MAIA) ("MAIA" or the "Company"), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today published a 2025 Shareholder Letter by CEO Vlad Vitoc, M.D. detailing the Company's key milestones for 2025 including several clinical trials and regulatory pathways. "MAIA continues to bring innovation
Poster highlights potential predictive biomarker for therapeutic response in advanced non-small cell lung cancer (NSCLC) MAIA Biotechnology, Inc., (NYSE:MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced that an abstract detailing a potential predictive biomarker for THIO treatment was selected for poster presentation at the European Lung Cancer Congress 2025 (ELCC 2025) taking place, March 26-29, in Paris, France. ELCC is a program of the European Society for Medical Oncology (ESMO). "We are proud to join ELCC 2025, a premier conference focused directly on the science of thoracic oncology," said V
Novel THIO dimer shows promise as a new compound with a dual mechanism of action for enhancing standard cancer treatments and overcoming resistance MAIA Biotechnology, Inc., (NYSE:MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announces the publication of preclinical data for its lead proprietary telomere-targeting THIO dimer in the peer-reviewed scientific journal Naunyn-Schmiedeberg's Archives of Pharmacology. In a preclinical study, THIO and its new described dimer form were found to be potent inhibitors of Glutathione S-transferase Pi (GSTP1), a key enzyme implicated in cancer progression and chemoresis
4 - MAIA Biotechnology, Inc. (0001878313) (Issuer)
4 - MAIA Biotechnology, Inc. (0001878313) (Issuer)
4/A - MAIA Biotechnology, Inc. (0001878313) (Issuer)
SC 13D/A - MAIA Biotechnology, Inc. (0001878313) (Subject)
SC 13D - MAIA Biotechnology, Inc. (0001878313) (Subject)
SC 13D - MAIA Biotechnology, Inc. (0001878313) (Subject)
4 - MAIA Biotechnology, Inc. (0001878313) (Issuer)
4 - MAIA Biotechnology, Inc. (0001878313) (Issuer)
4 - MAIA Biotechnology, Inc. (0001878313) (Issuer)
DEFA14A - MAIA Biotechnology, Inc. (0001878313) (Filer)
DEF 14A - MAIA Biotechnology, Inc. (0001878313) (Filer)
8-K - MAIA Biotechnology, Inc. (0001878313) (Filer)